GENFIT (GNFT) Competitors $3.80 -0.09 (-2.44%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNFT vs. AMLX, AVBP, IMTX, IMNM, NUVB, MGTX, GYRE, AUTL, PHAR, and DAWNShould you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include Amylyx Pharmaceuticals (AMLX), ArriVent BioPharma (AVBP), Immatics (IMTX), Immunome (IMNM), Nuvation Bio (NUVB), MeiraGTx (MGTX), Gyre Therapeutics (GYRE), Autolus Therapeutics (AUTL), Pharming Group (PHAR), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. GENFIT vs. Its Competitors Amylyx Pharmaceuticals ArriVent BioPharma Immatics Immunome Nuvation Bio MeiraGTx Gyre Therapeutics Autolus Therapeutics Pharming Group Day One Biopharmaceuticals GENFIT (NASDAQ:GNFT) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Is GNFT or AMLX more profitable? GENFIT's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets GENFITN/A N/A N/A Amylyx Pharmaceuticals N/A -77.21%-63.84% Do institutionals and insiders have more ownership in GNFT or AMLX? 2.2% of GENFIT shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 4.2% of GENFIT shares are owned by company insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate GNFT or AMLX? GENFIT presently has a consensus target price of $13.00, indicating a potential upside of 240.31%. Amylyx Pharmaceuticals has a consensus target price of $11.75, indicating a potential upside of 49.30%. Given GENFIT's higher possible upside, equities research analysts clearly believe GENFIT is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media prefer GNFT or AMLX? In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than GENFIT. MarketBeat recorded 4 mentions for Amylyx Pharmaceuticals and 0 mentions for GENFIT. Amylyx Pharmaceuticals' average media sentiment score of 0.44 beat GENFIT's score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment GENFIT Neutral Amylyx Pharmaceuticals Neutral Which has preferable earnings & valuation, GNFT or AMLX? GENFIT has higher earnings, but lower revenue than Amylyx Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENFIT$67.00M2.85$1.63MN/AN/AAmylyx Pharmaceuticals$87.37M8.03-$301.74M-$3.11-2.53 Which has more risk and volatility, GNFT or AMLX? GENFIT has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.49, meaning that its share price is 149% less volatile than the S&P 500. SummaryAmylyx Pharmaceuticals beats GENFIT on 8 of the 13 factors compared between the two stocks. Get GENFIT News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGENFITMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$191.01M$2.96B$5.57B$9.40BDividend YieldN/A2.47%4.00%4.02%P/E RatioN/A20.6728.3419.86Price / Sales2.85315.37444.43100.76Price / Cash54.1940.8024.9928.17Price / Book2.557.788.315.73Net Income$1.63M-$55.16M$3.23B$257.57M7 Day Performance0.95%6.39%4.19%3.90%1 Month Performance-1.67%16.81%10.14%14.28%1 Year Performance-12.59%3.05%34.71%17.44% GENFIT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGENFIT2.2851 of 5 stars$3.82-2.1%$13.00+240.3%-7.2%$191.01M$67.00M0.00120Upcoming EarningsGap UpAMLXAmylyx Pharmaceuticals3.1306 of 5 stars$8.41+9.5%$11.75+39.7%+306.4%$749.68M-$1.27M-2.70200High Trading VolumeAVBPArriVent BioPharma2.2055 of 5 stars$21.87+1.1%$39.29+79.6%+14.8%$748.24MN/A-5.8040News CoveragePositive NewsAnalyst ForecastIMTXImmatics3.0665 of 5 stars$6.11+2.3%$14.67+140.0%-53.3%$742.67M$168.65M-35.94260Positive NewsIMNMImmunome1.6067 of 5 stars$8.51-1.5%$23.33+174.2%-18.7%$740.46M$9.04M-2.6840NUVBNuvation Bio2.8458 of 5 stars$2.15-2.1%$7.17+232.7%-21.5%$732.92M$7.87M-0.9260MGTXMeiraGTx3.9197 of 5 stars$8.89+5.0%$24.00+170.0%+96.6%$714.40M$33.28M-3.83300GYREGyre Therapeutics0.0199 of 5 stars$7.61+1.6%N/A-53.2%$713.51M$105.76M380.6940AUTLAutolus Therapeutics2.6957 of 5 stars$2.65+7.3%$9.32+251.7%-42.8%$705.27M$10.12M-3.01330News CoverageAnalyst ForecastPHARPharming Group2.3802 of 5 stars$10.35+3.5%$30.00+189.9%+19.2%$704.12M$320.71M-51.75280Gap UpDAWNDay One Biopharmaceuticals2.9078 of 5 stars$6.93+2.1%$29.00+318.5%-57.3%$702.44M$161.92M-9.7660News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies Amylyx Pharmaceuticals Alternatives ArriVent BioPharma Alternatives Immatics Alternatives Immunome Alternatives Nuvation Bio Alternatives MeiraGTx Alternatives Gyre Therapeutics Alternatives Autolus Therapeutics Alternatives Pharming Group Alternatives Day One Biopharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNFT) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENFIT S.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GENFIT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
